CORRECTION 9 Meters Biopharma, Inc. to Present at Oppenheimer's Rare & Orphan Disease Summit

Rhea-AI Summary

9 Meters Biopharma (NASDAQ:NMTR) has announced that CEO John Temperato will present a corporate update at Oppenheimer's Rare & Orphan Disease Summit on May 21, 2021, from 3:45 - 4:25 p.m. ET. Investors can participate via a webcast and schedule one-on-one meetings with management. The company focuses on developing treatments for rare gastroenterological diseases, notably advancing vurolenatide and larazotide. A replay of the event will be available for 90 days after the presentation.

This version of the release contains a corrected hyperlink.

RALEIGH, NC / ACCESSWIRE / May 19, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that the Company's CEO, John Temperato will present a corporate update at Oppenheimer's
Rare & Orphan Disease Summit and invites investors to participate via webcast and in one-on-one meetings. Please see additional details below:

Oppenheimer's Rare & Orphan Disease Summit

Date: May 21, 2021
Time: 3:45 - 4:25 p.m. (ET)
Participation: Management will be available for 1-on-1 meetings
Webcast: https://wsw.com/webcast/oppenheimer12/nmtr/2813759

* a replay will be available following the presentation for 90 days

Please contact your representative at Oppenheimer & Co. to schedule a virtual one-on-one meeting with 9 Meters during the respective conference.

For more information about Oppenheimer's Rare & Orphan Disease Summit, please refer to the conference website.

About 9 Meters Biopharma
9 Meters Biopharma, Inc. ("the Company") is a rare and unmet needs-focused gastroenterology company. The Company is advancing vurolenatide, a proprietary long-acting GLP-1 agonist, into a Phase 2 trial for short bowel syndrome (SBS), a rare, orphan disease, as well as larazotide, a Phase 3 tight junction regulator being evaluated for symptom improvement in non-responsive celiac disease.

For more information, please visit www.9meters.com or follow 9 Meters on Twitter and LinkedIn.

Corporate Contacts:

Edward J. Sitar
Chief Financial Officer
9 Meters Biopharma, Inc.
investor-relations@9meters.com
www.9meters.com

Media Contact:

Veronica Eames
LifeSci Communications, LLC
veames@lifescicomms.com
203-942-4626

Investor Contact:

Corey Davis, Ph.D.
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
212-915-2577

SOURCE: 9 Meters Biopharma

View source version on accesswire.com:
https://www.accesswire.com/647961/CORRECTION-9-Meters-Biopharma-Inc-to-Present-at-Oppenheimers-Rare-Orphan-Disease-Summit

FAQ

What is 9 Meters Biopharma presenting at the Oppenheimer Summit?

9 Meters Biopharma's CEO John Temperato will present a corporate update at the Oppenheimer Rare & Orphan Disease Summit.

When is the Oppenheimer Rare & Orphan Disease Summit?

The Oppenheimer Rare & Orphan Disease Summit is scheduled for May 21, 2021.

What time will the presentation by 9 Meters occur?

The presentation will take place from 3:45 - 4:25 p.m. ET.

How can investors participate in the event?

Investors can participate via a webcast and schedule one-on-one meetings with 9 Meters management.

Where can I find more information about the event?

More information can be found on the Oppenheimer conference website.

What are the key drugs being developed by 9 Meters Biopharma?

9 Meters is advancing vurolenatide for short bowel syndrome and larazotide for non-responsive celiac disease.

How long will the presentation be available as a replay?

The replay of the presentation will be available for 90 days.